Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous dendritic cell vaccine for recurrent HPV16/18-positive cervical cancer
ChiCTR-OIC-16008915Phase 3Not yet recruiting
- Sponsor
- Jiangsu Antae Biological Technology
- Start
- Sep 2016
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of autologous dendritic cell vaccine in Cervical Cancer (CC), sponsored by Jiangsu Antae Biological Technology. Primary endpoint: HPV clearance. Planned start Sep 2016; status: not yet recruiting.
02
Drugs
autologous dendritic cell vaccine
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR-OIC-16008915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-16008915.